MESA LABORATORIES INC /CO/
Business
Mesa Laboratories, Inc. designs and manufactures life sciences tools and critical quality control solutions for regulated pharmaceutical, healthcare, and medical device applications. The company offers consumables, hardware, and services including biological and chemical sterilization indicators, genomic analysis instruments, protein analysis systems, peptide synthesis equipment, and calibration and monitoring solutions. Mesa operates four reportable segments: Sterilization and Disinfection Control, Biopharmaceutical Development, Clinical Genomics, and Calibration Solutions, with manufacturing in the United States and Europe and sales through direct personnel and independent distributors globally.
Summary from 10-K filed 2026-06-02
Financials
Consolidated Statement of Income
| Concept | Trend | Mar 31, 2026 2026-03-31 | Mar 31, 2025 2025-03-31 | Mar 31, 2024 2024-03-31 |
|---|---|---|---|---|
| Revenues: | — | — | — | |
| Revenue | 249 | 241 | 216 | |
| Cost of revenues: | — | — | — | |
| Cost of revenue | 91 | 90 | 83 | |
| Gross profit | 158 | 151 | 133 | |
| Operating expense: | — | — | — | |
| Selling | 41 | 42 | 39 | |
| General and administrative, other than impairment of finite-lived intangible assets and goodwill | 79 | 73 | 73 | |
| Research and development | 20 | 20 | 19 | |
| Impairment of finite-lived intangible assets | 0 | 0 | 118 | |
| Impairment of goodwill | 0 | 0 | 157 | |
| Total operating expense | 140 | 135 | 405 | |
| Operating income (loss) | 19 | 16 | −272 | |
| Nonoperating expense (income): | — | — | — | |
| Interest expense and amortization of debt issuance costs | 11 | 12 | 6 | |
| Gain on extinguishment of convertible senior notes | 0 | 3 | 0 | |
| Other (income) expense, net | 4 | −1 | 2 | |
| Total nonoperating expense, net | −6 | −10 | −4 | |
| Earnings (loss) before income taxes | 12 | 6 | −276 | |
| Income tax expense (benefit) | 5 | 8 | −21 | |
| Net income (loss) | 7 | −2 | −254 | |
| Net earnings (loss) per share | — | — | — | |
| Basic earnings (loss) per share (in dollars per share) | 1.22 | −0.36 | −47.2 | |
| Diluted earnings (loss) per share (in dollars per share) | 1.21 | −0.36 | −47.2 | |
| Weighted-average common shares outstanding | — | — | — | |
| Basic (in shares) | 6 | 5 | 5 | |
| Diluted (in shares) | 6 | 5 | 5 |
Consolidated Balance Sheet
| Concept | Trend | Mar 31, 2026 2026-03-31 | Mar 31, 2025 2025-03-31 |
|---|---|---|---|
| Current assets | — | — | |
| Cash and cash equivalents | 27 | 27 | |
| Accounts receivable, less allowances for credit losses of $2,569 and $1,186, respectively | 44 | 42 | |
| Inventories | 26 | 25 | |
| Prepaid expenses and other current assets | 9 | 8 | |
| Total current assets | 106 | 103 | |
| Noncurrent assets | — | — | |
| Property, plant and equipment, net | 31 | 32 | |
| Deferred tax asset | 2 | 1 | |
| Other Assets, Noncurrent | 19 | 18 | |
| Intangible assets | 83 | 97 | |
| Goodwill | 187 | 182 | |
| Total assets | 428 | 433 | |
| Accounts payable | 5 | 6 | |
| Accrued payroll and benefits | 19 | 18 | |
| Unearned revenues | 15 | 15 | |
| Other accrued expenses | 18 | 25 | |
| Term loan, current portion | 6 | 4 | |
| Convertible senior notes, current portion, net of debt issuance costs | 0 | 97 | |
| Total current liabilities | 62 | 164 | |
| Deferred tax liability | 20 | 20 | |
| Other Liabilities, Noncurrent | 14 | 12 | |
| Noncurrent portion | 61 | 67 | |
| Revolving line of credit | 85 | 10 | |
| Total liabilities | 242 | 274 | |
| Commitments and Contingencies (Note 13) | — | — | |
| Stockholders’ equity | — | — | |
| Common stock, no par value; authorized 25,000,000 shares; issued and outstanding, 5,524,931 and 5,455,421 shares, respectively | 375 | 359 | |
| (Accumulated deficit) | −186 | −189 | |
| Accumulated other comprehensive (loss) | −3 | −10 | |
| Total stockholders’ equity | 186 | 160 | |
| Total liabilities and stockholders’ equity | 428 | 433 |
Consolidated Statement of Cash Flows
| Concept | Trend | Mar 31, 2026 2026-03-31 | Mar 31, 2025 2025-03-31 | Mar 31, 2024 2024-03-31 |
|---|---|---|---|---|
| Cash flows from operating activities: | — | — | — | |
| Net income (loss) | 7 | −2 | −254 | |
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | — | — | — | |
| Depreciation of property, plant and equipment | 5 | 5 | 4 | |
| Amortization of acquisition-related intangibles | 18 | 19 | 27 | |
| Stock-based compensation expense | 18 | 13 | 12 | |
| Non-cash interest expense and debt issuance cost amortization | 682,000 | 990,000 | 926,000 | |
| Gain on extinguishment of convertible senior notes | 0 | 3 | 0 | |
| Amortization of step-up in inventory basis | 0 | 1 | 1 | |
| Deferred taxes | 1 | 72,000 | 28 | |
| Impairment loss on goodwill and finite-lived intangible assets | 0 | 0 | 275 | |
| Other | −577,000 | −5 | −629,000 | |
| Cash from changes in operating assets and liabilities: | — | — | — | |
| Accounts receivable | 3 | 3 | −5 | |
| Inventories | 4 | −1 | −3 | |
| Prepaid expenses and other assets | −608,000 | −498,000 | −211,000 | |
| Accounts payable | −1 | −388,000 | −97,000 | |
| Accrued liabilities and taxes payable | 3 | 10 | −1 | |
| Unearned revenues | −255,000 | −938,000 | −408,000 | |
| Net cash provided by operating activities | 43 | 47 | 44 | |
| Cash flows from investing activities: | — | — | — | |
| Purchases of property, plant and equipment | 3 | 4 | 3 | |
| Acquisition of customer lists | 0 | 250,000 | 0 | |
| Acquisition of businesses, net of cash acquired and holdback liabilities | 0 | 0 | 79 | |
| Net cash (used in) investing activities | −3 | −4 | −81 | |
| Cash flows from financing activities: | — | — | — | |
| Proceeds from debt borrowings | 108 | 73 | 71 | |
| Repurchase of convertible note debt | 98 | 72 | 0 | |
| Other debt principal repayments | 37 | 44 | 34 | |
| GKE acquisition holdback payment | 10 | 0 | 0 | |
| Dividends paid | 4 | 3 | 3 | |
| Payment of tax withholding obligation on vesting of restricted stock | 1 | 887,000 | 728,000 | |
| Proceeds from the exercise of stock options | 0 | 3 | 358,000 | |
| Other financing, net | −966,000 | −452,000 | −847,000 | |
| Net cash (used in) provided by financing activities | −42 | −45 | 33 | |
| Net (decrease) in cash and cash equivalents | −393,000 | −893,000 | −5 | |
| Cash and cash equivalents at end of period | — | — | — | |
| Cash and cash equivalents at end of period | — | — | — | |
| Effect of exchange rate changes on cash and cash equivalents | 2 | 1 | −359,000 | |
| Cash paid for: | — | — | — | |
| Income taxes | 2 | 6 | 5 | |
| Interest | 10 | 11 | 5 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is MESA LABORATORIES INC /CO/'s CIK number?
MESA LABORATORIES INC /CO/'s SEC CIK number is 0000724004 (724004). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find MESA LABORATORIES INC /CO/'s SEC filings?
All of MESA LABORATORIES INC /CO/'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did MESA LABORATORIES INC /CO/ last report earnings?
MESA LABORATORIES INC /CO/ (MLAB) most recently filed an earnings 8-K with the SEC on May 27, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0000724004-26-000039). This is MESA LABORATORIES INC /CO/'s most recent earnings filing of record — not a forecast of its next earnings date.
What is MESA LABORATORIES INC /CO/'s most recent earnings 8-K?
MESA LABORATORIES INC /CO/'s latest earnings 8-K (Item 2.02) was filed May 27, 2026 under accession 0000724004-26-000039. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View MESA LABORATORIES INC /CO/'s latest earnings 8-K →
Look up any company's CIK number →